Tesaro Inc (TSRO) 27.82 $TSRO
TESARO (TSRO) Slips on Wider-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 2:10PM CDT
TESARO (TSRO) reported second-quarter loss of $1.00 per share, wider than the Zacks Consensus Estimate of a loss of 89 cents and year-ago loss of 67 cents.
TESARO Appoints Mary Lynne Hedley, Ph.D., as Chief Operating Officer
GlobeNewswire - Thu Jul 24, 3:09PM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that Mary Lynne Hedley, Ph.D., President and Co-Founder of TESARO, has been appointed to the role of Chief Operating Officer.
TESARO Announces Second-Quarter 2014 Operating Results
GlobeNewswire - Thu Jul 24, 3:09PM CDT
-- Oral Rolapitant New Drug Application (NDA) on Track for Submission to U.S. FDA
Myriad Genetics Poised on Strong Fundamentals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 5:10PM CDT
On July 9, we issued an updated research report on leading molecular diagnostic company Myriad Genetics Inc. (MYGN).
TESARO to Announce Second-Quarter 2014 Financial Results on July 24, 2014
GlobeNewswire - Thu Jul 10, 3:01PM CDT
TESARO, Inc. (Nasdaq:TSRO) will announce its second-quarter 2014 financial results on Thursday, July 24, 2014, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on July 24, 2014 to discuss the Company's results in greater detail.
3 Big Stocks on Traders' Radars
at The Street - Wed Jul 09, 1:51PM CDT
Here's how to trade some of the most active stocks on the market today.
'Fast Money' Recap: Waiting for the Dust to Settle
at The Street - Wed Jul 09, 4:00AM CDT
The trading panel discussed the market's fall and how to hedge your positions.
Tesaro (TSRO) in Focus: Stock Moves 8.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 8:46AM CDT
Tesaro (TSRO) was a big mover last session, with shares rising nearly 9% on the day.
Market Expansion, Merger Agreements, Management Transitions, and Market Activity - Analyst Notes on Intuitive Surgical, Auxilium, Horizon Pharma, Tesaro and ArQule
PR Newswire - Wed Jul 02, 5:30AM CDT
Today, Analysts Review released its analysts' notes regarding Intuitive Surgical, Inc. (NASDAQ: ISRG), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Horizon Pharma, Inc. (NASDAQ: HZNP), Tesaro, Inc. (NASDAQ: TSRO) and ArQule Inc. (NASDAQ: ARQL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4352-100free.
Nasdaq stocks posting largest percentage increases
AP - Tue Jul 01, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
TESARO Summarizes Rolapitant Data Presented at the 2014 MASCC/ISOO International Symposium on Supportive Care in Cancer
GlobeNewswire - Fri Jun 27, 10:00AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that three oral presentations detailing the final results from the rolapitant registration program were delivered today at the MASCC/ISOO International Symposium on Supportive Care in Cancer annual meeting in Miami. Rolapitant is an investigational neurokinin-1 (NK-1) receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV).
Tesaro Summarizes Phase 3 Rolapitant Data Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting and Provides an Update on Niraparib Development Strategy
GlobeNewswire - Sun Jun 01, 6:15PM CDT
-- Oral Rolapitant New Drug Application (NDA) Submission on Track for Mid-2014
TESARO Appoints Tim Pearson as Chief Financial Officer
GlobeNewswire - Tue May 27, 3:01PM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Tim Pearson as Chief Financial Officer. Mr. Pearson was most recently Executive Vice President and Chief Financial Officer of Catalyst Health Solutions, Inc., where he led the finance and strategic planning functions. Previously, Mr. Pearson served in a number of financial executive roles at MedImmune, the biologics division of AstraZeneca, including the positions of Executive Vice President and Chief Financial Officer, Vice President of Finance, and Treasurer. During his thirteen year tenure at MedImmue, prior to its acquisition by AstraZenca, Mr. Pearson was involved with commercial launches, marketing partnerships, in-licensing transactions and several acquisitions.
TESARO Announces Webcast of Investor & Analyst Briefing at ASCO
GlobeNewswire - Tue May 27, 7:01AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, invites investors and the general public to listen to a webcast of an investor briefing scheduled for Sunday, June 1 at 6:15 PM Central time in conjunction with the 2014 American Society of Clinical Oncology (ASCO) annual meeting. At this briefing, TESARO management will review rolapitant clinical data, discuss the niraparib development strategy and provide an update on its TSR-011 and immuno-oncology programs. In addition, Jeffrey Patton, M.D. of Tennessee Oncology, a practicing oncologist with extensive experience in the treatment of patients with a variety of cancers, and Drew Pardoll, M.D., Ph.D. of Johns Hopkins University, an expert in immuno-oncology approaches such as those targeting PD-1, TIM-3, LAG-3 and other immune regulators, will take part in discussions with investors.
TESARO Announces Data Presentations At 2014 AACR Annual Meeting
GlobeNewswire - Wed Apr 02, 8:43AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that two posters highlighting its niraparib and immuno-oncology programs will be presented at the American Association of Cancer Research (AACR) meeting, which will take place April 5-9, 2014 in San Diego, California.
Why 2014 May Be a Big Year for Opko Health, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 28, 9:27PM CDT
Philip Frost has never been shy about backing his investments. Frost, the former founder of IVAX , and Chairman of generic heavyweight Teva Pharmaceuticals , has big stakes in a variety of emerging health-care companies. However, out of all his...
Myriad Genetics Inks HRD Alliance with Tesaro - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 2:00PM CDT
Recently Myriad Genetics entered into a companion diagnostics research collaboration with pharmaceutical major Tesaro.
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 26, 4:20PM CDT
I follow quite a lot of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
Myriad Announces HRD Companion Diagnostic Collaboration With Tesaro
GlobeNewswire - Mon Mar 24, 6:05AM CDT
Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Tesaro, Inc. will use Myriad's novel HRD (homologous recombination deficiency) test to identify tumor types that may respond to its investigational poly-ADP ribose polymerase (PARP) inhibitor, niraparib, currently in Phase 3 clinical development. Specific terms of the deal were not disclosed.
Biotech Stock Mailbag: Amarin, Cytrx, Sangamo and 'Story Stocks'
at The Street - Fri Mar 21, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
TESARO (TSRO) Slips on Wider-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 2:10PM CDT
TESARO (TSRO) reported second-quarter loss of $1.00 per share, wider than the Zacks Consensus Estimate of a loss of 89 cents and year-ago loss of 67 cents.
TESARO Appoints Mary Lynne Hedley, Ph.D., as Chief Operating Officer
GlobeNewswire - Thu Jul 24, 3:09PM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that Mary Lynne Hedley, Ph.D., President and Co-Founder of TESARO, has been appointed to the role of Chief Operating Officer.
TESARO Announces Second-Quarter 2014 Operating Results
GlobeNewswire - Thu Jul 24, 3:09PM CDT
-- Oral Rolapitant New Drug Application (NDA) on Track for Submission to U.S. FDA
Myriad Genetics Poised on Strong Fundamentals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 5:10PM CDT
On July 9, we issued an updated research report on leading molecular diagnostic company Myriad Genetics Inc. (MYGN).
TESARO to Announce Second-Quarter 2014 Financial Results on July 24, 2014
GlobeNewswire - Thu Jul 10, 3:01PM CDT
TESARO, Inc. (Nasdaq:TSRO) will announce its second-quarter 2014 financial results on Thursday, July 24, 2014, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on July 24, 2014 to discuss the Company's results in greater detail.
3 Big Stocks on Traders' Radars
at The Street - Wed Jul 09, 1:51PM CDT
Here's how to trade some of the most active stocks on the market today.
'Fast Money' Recap: Waiting for the Dust to Settle
at The Street - Wed Jul 09, 4:00AM CDT
The trading panel discussed the market's fall and how to hedge your positions.
Tesaro (TSRO) in Focus: Stock Moves 8.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 8:46AM CDT
Tesaro (TSRO) was a big mover last session, with shares rising nearly 9% on the day.
Market Expansion, Merger Agreements, Management Transitions, and Market Activity - Analyst Notes on Intuitive Surgical, Auxilium, Horizon Pharma, Tesaro and ArQule
PR Newswire - Wed Jul 02, 5:30AM CDT
Today, Analysts Review released its analysts' notes regarding Intuitive Surgical, Inc. (NASDAQ: ISRG), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Horizon Pharma, Inc. (NASDAQ: HZNP), Tesaro, Inc. (NASDAQ: TSRO) and ArQule Inc. (NASDAQ: ARQL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4352-100free.
Nasdaq stocks posting largest percentage increases
AP - Tue Jul 01, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
TESARO Summarizes Rolapitant Data Presented at the 2014 MASCC/ISOO International Symposium on Supportive Care in Cancer
GlobeNewswire - Fri Jun 27, 10:00AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that three oral presentations detailing the final results from the rolapitant registration program were delivered today at the MASCC/ISOO International Symposium on Supportive Care in Cancer annual meeting in Miami. Rolapitant is an investigational neurokinin-1 (NK-1) receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV).
Tesaro Summarizes Phase 3 Rolapitant Data Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting and Provides an Update on Niraparib Development Strategy
GlobeNewswire - Sun Jun 01, 6:15PM CDT
-- Oral Rolapitant New Drug Application (NDA) Submission on Track for Mid-2014
TESARO Appoints Tim Pearson as Chief Financial Officer
GlobeNewswire - Tue May 27, 3:01PM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Tim Pearson as Chief Financial Officer. Mr. Pearson was most recently Executive Vice President and Chief Financial Officer of Catalyst Health Solutions, Inc., where he led the finance and strategic planning functions. Previously, Mr. Pearson served in a number of financial executive roles at MedImmune, the biologics division of AstraZeneca, including the positions of Executive Vice President and Chief Financial Officer, Vice President of Finance, and Treasurer. During his thirteen year tenure at MedImmue, prior to its acquisition by AstraZenca, Mr. Pearson was involved with commercial launches, marketing partnerships, in-licensing transactions and several acquisitions.
TESARO Announces Webcast of Investor & Analyst Briefing at ASCO
GlobeNewswire - Tue May 27, 7:01AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, invites investors and the general public to listen to a webcast of an investor briefing scheduled for Sunday, June 1 at 6:15 PM Central time in conjunction with the 2014 American Society of Clinical Oncology (ASCO) annual meeting. At this briefing, TESARO management will review rolapitant clinical data, discuss the niraparib development strategy and provide an update on its TSR-011 and immuno-oncology programs. In addition, Jeffrey Patton, M.D. of Tennessee Oncology, a practicing oncologist with extensive experience in the treatment of patients with a variety of cancers, and Drew Pardoll, M.D., Ph.D. of Johns Hopkins University, an expert in immuno-oncology approaches such as those targeting PD-1, TIM-3, LAG-3 and other immune regulators, will take part in discussions with investors.
TESARO Announces Data Presentations At 2014 AACR Annual Meeting
GlobeNewswire - Wed Apr 02, 8:43AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that two posters highlighting its niraparib and immuno-oncology programs will be presented at the American Association of Cancer Research (AACR) meeting, which will take place April 5-9, 2014 in San Diego, California.
Why 2014 May Be a Big Year for Opko Health, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 28, 9:27PM CDT
Philip Frost has never been shy about backing his investments. Frost, the former founder of IVAX , and Chairman of generic heavyweight Teva Pharmaceuticals , has big stakes in a variety of emerging health-care companies. However, out of all his...
Myriad Genetics Inks HRD Alliance with Tesaro - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 2:00PM CDT
Recently Myriad Genetics entered into a companion diagnostics research collaboration with pharmaceutical major Tesaro.
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 26, 4:20PM CDT
I follow quite a lot of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
Myriad Announces HRD Companion Diagnostic Collaboration With Tesaro
GlobeNewswire - Mon Mar 24, 6:05AM CDT
Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Tesaro, Inc. will use Myriad's novel HRD (homologous recombination deficiency) test to identify tumor types that may respond to its investigational poly-ADP ribose polymerase (PARP) inhibitor, niraparib, currently in Phase 3 clinical development. Specific terms of the deal were not disclosed.
Biotech Stock Mailbag: Amarin, Cytrx, Sangamo and 'Story Stocks'
at The Street - Fri Mar 21, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
